title: Evidence based medicine in the use of botulinum toxin for back pain.
abstract: Two randomized, prospective studies, one double blind and one open label, longterm evaluated efficacy and safety of Botulinum toxin A (Allergan-Inc) in 31 and 75 patients with chronic low back pain. Both studies used a novel technique imploying 5 level (L1 to L5) injections (40-50 units/level) of BoNT-A into erector spinae muscles. Significant (p < 0.05) improvement of pain intensity, frequency and activities of daily living was noted in 60% and 53% of the patients, respectively. The second study also depicted safety with repeated injections over 14 months of follow up. Botulinum toxin-A should be considered for treatment of low back pain when other modes of treatment fail to improve pain.
authors: Department of Neurology, Yale University School of Medicine, New Haven, CT 06520, USA. bahman.jabbari@yale.edu
authors: B
authors: B
authors: Jabbari
mesh_terms: D018726:Anti-Dyskinesia Agents / Q000627:therapeutic use*; D001416:Back Pain / Q000188:drug therapy*; D001905:Botulinum Toxins / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D010147:Pain Measurement
chemical_list: D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins